Trials / Completed
CompletedNCT02093533
Eculizumab in Primary MPGN
EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Mario Negri Institute for Pharmacological Research · Academic / Other
- Sex
- All
- Age
- 75 Years
- Healthy volunteers
- Not accepted
Summary
Membranoproliferative glomerulonephritis (MPGN) is the third or fourth leading cause of end stage renal disease among the primary glomerulonephritis. Hyperactivation of the alternative complement pathway and familial forms for all types of MPGN have been reported suggesting that genetic abnormalities may play a predisposing role to the disease. In recent case reports Eculizumab, a monoclonal antibody that binds to C5 to prevent formation of the membrane attack complex ,is a safe and effective therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eculizumab |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2017-12-01
- Completion
- 2017-12-01
- First posted
- 2014-03-21
- Last updated
- 2018-01-17
Locations
13 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT02093533. Inclusion in this directory is not an endorsement.